Including clinical risk into biomarker-based cancer pre-screening assessment

By combining individual clinical risk scores and genomic risk scores, the size and density data of cell free DNA fragments are analyzed, and the problem of ignoring clinical risk factors in existing cancer pre-screening is solved, which improves the sensitivity and specificity of cancer pre-screening and reduces the number of LDCT screening times.

CN120359307APending Publication Date: 2025-07-22DELFI DIAGNOSTICS INC
0 Cites 0 Cited by

Patent Information

Application Number
CN202380070413.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-07
Filing Date
2023-10-06
Publication Date
2025-07-22

AI Technical Summary

Technical Problem

The existing cancer prescreening methods rely on genomic characteristics and ignore individual clinical risk factors, resulting in insufficient screening efficiency and accuracy.

Method used

Combining individual clinical risk scores and genomic risk scores, cfDNA fragment size and density data are generated by analyzing cell free DNA fragment size and density data to improve the accuracy and efficiency of cancer pre-screening.

Benefits of technology

It improves the sensitivity and specificity of cancer prescreening, reduces the number of standard low-dose computed tomography (LDCT) screenings, and improves the recognition rate of potential cancer individuals.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses a method for cancer pre-screening of a subject. Genetic risks associated with genetic characteristics are determined by sequencing and analyzing cell free DNA ("cfDNA") fragments present in a blood sample of the subject. The clinical risk is determined based on factors such as age, gender, and race. In some cases, clinical factors specific to certain cancers, such as smoking conditions, are combined. By incorporating clinical risks into genomic risk analysis, improved lung cancer pre-screening results are provided, enabling the same number of positive cancer detections to be achieved using a small number of LDCT lung cancer screening times.
Need to check novelty before this filing date? Find Prior Art